News

In an interview with Targeted Oncology, Nazli Dizman, MD, discussed the role of gut microbiome in cancer and speaks to her presentation given at IKCS.

An application for approval of a new dosing schedule of Rylaze has been submitted to the FDA.

The MOMENTUM trial of momelotinib showed efficacy in treating symptoms of myelofibrosis, according to a press release.

Specially trained professionals working together are required to ensure that oncologic pharmaceuticals are used safely and effectively so that patients achieve optimal clinical outcomes.

Florida Cancer Specialist & Research Institute is the leading community-based oncology practice in Florida with clinical trial opportunities made available to patients at 36 locations in the state.

In an interview with Targeted Oncology, David S. Hong, MD, discussed the mark tisotumab vedotin has made on the metastatic cervical cancer landscape thus far.

In an interview with Targeted Oncology, Yelena Ginzburg, MD, discussed the research and use of rusfertide in patients with polycythemia vera.

The label for axicabtagene ciloleucel now includes prophylactic corticosteroids use in all approved indications.

Dosing of nanatinostat and valganciclovira in a phase1b/2 clinical trial has been initiated.

Topline results from an international phase 1 study of cosibelimab are encouraging and may lead to the submission of a biologics license application to the FDA.

Ahead of its Prescription Drug User Fee Act target action date, the supplemental biologics license application for cemiplimab as treatment of metastatic cervical cancer has been withdrawn.

Investigators of the GEMSTONE-302 trial announced finding a statistically significant benefit in overall survival with sugemalimab in patients with non–small cell lung cancer.

DZD9008 for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring with EGFR exon20 insertion mutations is an investigative treatment strategy in a clinical trial.

Patients with gastrointestinal cancers are being enrolled to a phase 1/2 of pelareorep in combination with atezolizumab.

The FDA has granted a fast-track designation to the G-quadruplex stabilizer CX-5461 for BRCA1/2, PALB2, or HRD mutations in their breast or ovarian cancer.

With a partial clinical hold placed by the FDA, all studies of magrolimab plus azacitidine must halt screening and enrollment.

Major clinical trials are looking to answer substantial questions in the treatment of patients with chronic lymphocytic leukemia, according to Matthew Davids, MD, MMSc.

Tebentafusp-tebn has been granted FDA approval to treat HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma based on positive results from a phase 3 study.

Results presented during the 2022 January ASCO Plenary Series showed that ripretinib did perform better than sunitinib in terms of the objective response rate, and the safety profile of the drug was favorable compared with sunitinib.

Globally, there is no established standard of care treatment for this patient population once patients failed on front-line platinum-based chemotherapy. Lenvatinib plus pembrolizumab is a new option.

A 67-year-old woman presented with a painless lump on her neck. A physical examination showed a palpable, nontender solitary neck mass to the right of the midline.

For the treatment of patients with myelodysplastic syndrome, the FDA has granted an orphan drug designation to eltanexor.

In an interview with Targeted Oncology, Shannon N. Westin, MD, MPH, FACOG, reviewed the recent tweet chat around a high-grade epithelial ovarian cancer case.

The anti-CD47 antibody, AO-176, has been granted an FDA orphan drug designation for relapsed or refractory myeloma treatment and is being assessed in a phase 1/2 study.

The KOMET-001 study may resume after the FDA lifted the partial clinical hold for safety.

LIBRETTO-531 succeeds LIBRETTO-001 to continue the study of selpercatinib in patients with multikinase inhibitor therapy-naive RET-mutant advanced medullary thyroid cancer.

Results from the ongoing phase 3 MOMENTUM clinical trial may be available by the end of Janaury 2022.

In an interview with Targeted Oncology, Ron Bose, MD, MPH, discussed HER2 drug resistance, its impact on treatment, and how new research may help in the future.

With an orphan drug designation in tow, MT-601 will soon be investigated in combination with chemotherapy in phase 1 clinical trial.